BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study
Abstract
No abstract availableKeywords
Funding Information
- National Center for Advancing Translational Sciences
- National Cancer Institute
This publication has 10 references indexed in Scilit:
- Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD modelsWorld Journal of Gastroenterology, 2018
- Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide surveyJournal of Gastroenterology, 2017
- Applicability of BALAD score in prognostication of hepatitis B‐related hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2015
- Hepatocellular carcinoma epidemiologyBest Practice & Research Clinical Gastroenterology, 2014
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD modelBritish Journal of Cancer, 2014
- Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: A Comparison of the Biomarker-Combined Japan Integrated Staging Score, the Conventional Japan Integrated Staging Score and the BALAD ScoreOncology, 2008
- Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum MarkersClinical Gastroenterology and Hepatology, 2006
- Relationship between Lens culinaris agglutinin‐reactive α‐fetoprotein and pathologic features of hepatocellular carcinomaLiver International, 2005
- Des-?-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinomaCancer, 2001